Index of Published Newsletters
The Health Product InfoWatch
March 2019
- Health products mentioned in this issue
- Announcement – Comparative effectiveness and safety of biosimilar drugs
- Announcement – Program launch: Help Stop Illegal Marketing of Drugs and Devices
- Announcement – Public access to clinical information on drugs and medical devices
- Monthly recap
- New information
February 2019
- Health products mentioned in this issue
- Announcement – Update on Biologics Naming
- Monthly recap
- New information
January 2019
- Announcement – Trelegy Ellipta
- Opioid Updates
- Monthly recap
- New information
- Review article: Prolonged use of hydrochlorothiazide and the risk of non-melanoma skin cancer
- Vaccine safety biannual summary: Report for January 1, 2018 to June 30, 2018
- Product monograph update: Biaxin BID, Biaxin XL, and Biaxin (clarithromycin)
- Product monograph update: Lamictal (lamotrigine)
- Product monograph update: Revlimid (lenalidomide)
December 2018
- Announcement – Annual trends for adverse reaction case reports and medical device incident reports (2008-2017)
- Announcement – Talc and the risk to human health
- Opioid Updates
- Monthly recap
- New information
November 2018
- Monthly recap
- New information
- Review article: Lamotrigine and international reports of hemophagocytic lymphohistiocytosis (HLH)
- Product monograph updates: Kayexalate (sodium polystyrene sulfonate) and Resonium Calcium (calcium polystyrene sulfonate)
- Product monograph update: Rifadin (rifampin)
- Notice of market authorization with conditions: Folotyn (pralatrexate injection)
October 2018
September 2018
- Announcement: Change to medical device audit process impacting product availability
- Announcement: Opioid marketing and advertising - share your stories
- Monthly recap
- New information
August 2018
July 2018
June 2018
May 2018
- Announcement: New regulations to provide better information for patients on the safe use of opioid medications
- Monthly recap
- New information
- Product monograph update: Dipeptidylpeptidase-4 (DPP-4) Inhibitors
- Product monograph update: Elavil (amitriptyline hydrochloride)
- Product monograph update: Gadolinium-Based Contrast Agents
- Product monograph update: Imitrex injection (sumatriptan succinate)
- Product monograph update: Revlimid (lenalidomide)
- Product monograph update: Zydelig (idelalisib)
- Notice of Market Authorization with Conditions: Bavencio (avelumab)
- Notice of Market Authorization with Conditions: Imfinzi (durvalumab)
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
- Announcement: Recalls and safety alerts mobile application
- Monthly recap
- New information
- Product monograph update: Product monograph update: Invokana (canagliflozin) and Invokamet (canagliflozin and metformin hydrochloride)
- Product monograph update: Revlimid (lenalidomide)
- Product monograph update: Temodal (temozolomide)
- Product monograph update: Videx EC (didanosine)
- Product monograph update: Zelboraf (vemurafenib)
- Vaccine safety quarterly summary: Report for October 1, 2016 to December 31, 2016
July 2017
June 2017
May 2017
April 2017
- Monthly recap
- New information
- Product monograph update: Amiodarone (intravenous)
- Product monograph update: Primaquine (primaquine phosphate)
- Product monograph update: Seroquel (quetiapine fumarate) and Seroquel XR (quetiapine fumarate extended-release)
- Product monograph update: Tecfidera (dimethyl fumarate)
- Product monograph update: Valproate products (valproic acid, divalproex sodium)
March 2017
February 2017
- Announcement
- Monthly recap
- New information
- Review article: Colorectal stents and bevacizumab: increased risk of intestinal perforation
- Vaccine safety quarterly summary: Report for April 1, 2016 to June 30, 2016
- Product monograph update: Tramadol-containing products
- Product monograph update: Votrient (pazopanib)
- Product monograph update: Zyprexa (olanzapine)
January 2017
December 2016
November 2016
October 2016
- Announcement
- Monthly recap
- New information
- Case report: Green Tea Triple Fat Burner - risk of drug-induced liver injury
- Product monograph update: Aczone (dapsone topical gel 5%)
- Product monograph update: Edarbyclor (azilsartan medoxomil and chlorthalidone)
- Product monograph update: Ferrlecit (sodium ferric gluconate complex in sucrose injection)
- Product monograph update: Intuniv XR (guanfacine)
- Product monograph update: Pomalyst (pomalidomide)
- Product monograph update: Solu-Medrol (methylprednisolone sodium succinate) Act-O-Vial 40 mg
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
- Monthly recap
- New information
- Review article: Pseudoephedrine and ischemic colitis
- Product confusion alert: Risk of eye injury with improper use of hydrogen peroxide-based contact lens solutions
- Vaccine safety review: Report for April 1, 2015 to June 30, 2015
- Product Monograph Updates: Piperacillin/Tazobactam for Injection and Piperacillin for Injection
January 2016
November 2015
- Monthly recap
- Case report: International case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol use
- Product confusion alert: Health product name confusion: Bio-K Plus and Bio K 20 Potassium
- Vaccine safety review: Report for January 1, 2015 to March 31, 2015
- Product monograph and medical device instructions for use updates: Hormonal and non-hormonal intrauterine systems/devices
September 2015
July 2015
June 2015
May 2015
March 2015
January 2015
Canadian Adverse Reaction Newsletters
- Pico-Salax (sodium picosulfate/magnesium citrate) and convulsions
- Risperidone and rhabdomyolysis independent of neuroleptic malignant syndrome
- Docetaxel and serious respiratory-related adverse reactions
- Case presentation: Ear drops containing peanut oil and suspected association with anaphylaxis
- Summary of advisories
- Second-generation antipsychotics and cardiometabolic adverse reactions in children and adolescents
- Prescription drugs and pediatric patients
- Canadian Paediatric Surveillance Program
- Adverse reaction reporting in children: update
- Adverse reaction reporting form
- Did you know? The Drug Safety and Effectiveness Network (DSEN) and pediatric projects
- Summary of advisories
- Proton pump inhibitors: hypomagnesemia accompanied by hypocalcemia and hypokalemia
- Adverse reaction and incident reporting -- 2010
- Case presentation: Floseal hemostatic matrix and suspected association with misinterpretation as recurrent malignant disease
- Risk communication information
- Summary of advisories
October 1999;9(4)
- Serious hematologic reactions associated with ticlopidine - update
- Leukotriene receptor antagonists: suspected adverse reactions
- Communiqué - Ropinirole (Requip): sleep disorder
July 1999; 9(3)
- Alteplase (Activase rt-PA) for acute ischemic stroke
- Abciximab (ReoPro): risk of acute thrombocytopenia
- Nefazodone (Serzone) and hepatotoxicity
- Communiqué - Amlodipine (Norvasc): hearing loss
April 1999; 9(2)
- Bupropion (Zyban): suspected adverse reactions
- 1998 ADR Statistics
- Updates: immune globulin IV products, tolcapone (Tasmar)
- Communiqué - Olanzapine (Zyprexa): priapism
January 1999; 9(1)
- Isotretinoin and depression
- Low-dose ASA and GI Bleeding
- Guidelines for reporting ADRs
- Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction
October 1998; 8(4)
- Recent News About Drug Risks
- New Ontario Regional ADR Centre
- Discontinuation Reactions Associated With SSRIs
- Communiqué - amantadine and warfarin, pantoprazole
July 1998; 8(3)
- Quality Information in Spontaneous Reports
- Donepezil: Suspected Adverse Reactions
- Olanzapine: Hematological Reactions
- Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors
April 1998; 8(2)
- Alendronate-induced esophagitis
- 1997 ADR statistics
- Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium, risperidone, venlafaxine hydrochloride
January 1998; 8(1)
- Drugs: QT interval prolongation and torsades de pointes
- Ciprofloxacin use in epileptic patients taking phenytoin
- Appetite suppressants - update
- Communiqué - vigabatrin, mefloquine, lamotrigine
October 1997; 7(4)
- Calcium-channel blockers
- Azithromycin - severe iatrogenic hepatitis
- Newsletter survey results
- Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine
July 1997; 7(3)
- ACE inhibitors and bronchospasm
- Interferon beta-1b
- Radiopharmaceuticals
- New Expert Advisory Committee on Pharmacovigilance
April 1997; 7(2)
- Adverse drug reaction reporting - 1996
- Potential abuse of butorphanol nasal spray
- Aminoglycoside ear drops and ototoxicity
January 1997; 7(1)
- Primary pulmonary hypertension and appetite suppressants
- HIV protease inhibitors and increased bleeding in hemophilia?
- Erythema multiforme and nifedipine
- Congenital anomalies and fluconazole
October 1996; 6(4)
- Cefaclor-associated serum sickness-like reaction
- Newsletter Assessment - Questionnaire
July 1996; 6(3)
- Cisapride: Arrhythmia Awareness
- Midazolam: A Wake-Up Call
- Clarithromycin: Tooth Discolouration and Smell Alteration
April 1996; 6(2)
- Metformin: Lactic Acidosis
- Nefazodone: ADR Profile
- 1995 Statistics ADR or Product Fault?
January 1996; 6(1)
- Cotrimoxazole
- Nicotine Patches and exercise
- Terbinafine - hepatobiliary reactions
- SSRIs - hyponatremia
October 1995; 5(4)
- Update: Fertility Drugs
- Propofol: Convulsions
- Contraindications: Dinoprostone
- Vaginal Gel
- DOCI List
July 1995; 5(3)
- Reporting Adverse Drug Reactions
- Lamotrigine (Lamictal): rashes
- Drug Names: confusion from two fronts
- Tiaprofenic Acid: cystitis
- Ticlopidine: revisited
- DOCI List
April 1995; 5(2)
- Zidovudine: Benefits of use during pregnancy
- Serevent®: Patient warnings must be stressed
- Fluoroquinolones: Tendonitis
- Topical Antifungals: Recent switch to over-the-counter
- Phenazopyridine: Hemolytic anemia
January 1995; 5(1)
- Risperidone and EPS Sumatriptan and migraine exacerbation
- Bromocriptine
- Fertility drug awareness
- New regional centre for Quebec
October 1994; 4(3)
- Regional Centres
- New Drugs - Serzone, Neurontin, Sabril
- Drugs of current interest
July 1994; 4(2)
- Editorial Note
- Terbinafine Herbal preparations
March 1994; 4(1)
- Rhabdomyolysis and HMG-CoA
- Reductase Inhibitors
- Antidepressants and Suicide
- Help Wanted: Risperdal
November 1993; 3(2)
- Ticlopidine HCl - Hematological and Liver Effects
- H1-Antihistamines - Cardiotoxic Effects
August 1993; 3(1)
- ACE Inhibitors: Renal Effects
- Sumatriptan Succinate: Chest Pain
- Nicotine Patches: Update / Inadvertent Exposure
April 1992; 2(1)
- ADR Program, 1991 Annual Report
- Case Report: Drug Interactions with Omeprazole
- Vasospasm with B-Blockers
- GI Bleeding with Toradol®
August 1991; 1(2)
- PPSP Workshop Minocycline - Case reports of severe liver and renal reactions
- ADRs in the Elderly Ciprofloxacin - ADR profile Diclofenac - Hepatic reactions
January 1991; 1(1)
- Saskatchewan ADR Pilot Project
- The WHO Connection Working Group on ADR Assessment
Report a problem or mistake on this page
- Date modified: